|
1.
|
Prat A and Perou CM: Mammary development
meets cancer genomics. Nat Med. 15:842–844. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Cheang MC, Chia SK, Voduc D, Gao D, Leung
S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM,
Ellis MJ and Nielsen TO: Ki67 index, HER2 status, and prognosis of
patients with luminal B breast cancer. J Natl Cancer Inst.
101:736–750. 2009. View Article : Google Scholar
|
|
3.
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal
therapy for early breast cancer on recurrence and 15-year survival:
an overview of the randomised trials. Lancet. 365:1687–1717.
2005.PubMed/NCBI
|
|
4.
|
Aitken SJ, Thomas JS, Langdon SP, Harrison
DJ and Faratian D: Quantitative analysis of changes in ER, PR and
HER2 expression in primary breast cancer and paired nodal
metastases. Ann Oncol. 21:1254–1261. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Osborne CK, Bardou V, Hopp TA, Chamness
GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM and Schiff
R: Role of the estrogen receptor coactivator AIB1 (SRC-3) and
HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer
Inst. 95:353–361. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Dowsett M, Houghton J, Iden C, Salter J,
Farndon J, A'Hern R, Sainsbury R and Baum M: Benefit from adjuvant
tamoxifen therapy in primary breast cancer patients according
oestrogen receptor, progesterone receptor, EGF receptor and HER2
status. Ann Oncol. 17:818–826. 2006. View Article : Google Scholar
|
|
7.
|
Dihge L, Bendahl PO, Grabau D, Isola J,
Lövgren K, Rydén L and Fernö M: Epidermal growth factor receptor
(EGFR) and the estrogen receptor modulator amplified in breast
cancer (AIB1) for predicting clinical outcome after adjuvant
tamoxifen in breast cancer. Breast Cancer Res Treat. 109:255–262.
2008. View Article : Google Scholar
|
|
8.
|
Hurtado A, Holmes KA, Geistlinger TR,
Hutcheson IR, Nicholson RI, Brown M, Jiang J, Howat WJ, Ali S and
Carroll JS: Regulation of ERBB2 by oestrogen receptor-PAX2
determines response to tamoxifen. Nature. 456:663–666. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Ball LJ, Levy N, Zhao X, Griffin C,
Tagliaferri M, Cohen I, Ricke WA, Speed TP, Firestone GL and
Leitman DC: Cell type-and estrogen receptor-subtype specific
regulation of selective estrogen receptor modulator regulatory
elements. Mol Cell Endocrinol. 299:204–211. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Kirkegaard T, McGlynn LM, Campbell FM,
Müller S, Tovey SM, Dunne B, Nielsen KV, Cooke TG and Bartlett JM:
Amplified in breast cancer 1 in human epidermal growth factor
receptor - positive tumors of tamoxifen-treated breast cancer
patients. Clin Cancer Res. 13:1405–1411. 2007. View Article : Google Scholar
|
|
11.
|
Pérez-Tenorio G and Stål O: Activation of
AKT/PKB in breast cancer predicts a worse outcome among endocrine
treated patients. Br J Cancer. 86:540–545. 2002.
|
|
12.
|
Leary AF, Drury S, Detre S, Pancholi S,
Lykkesfeldt AE, Martin LA, Dowsett M and Johnston SR: Lapatinib
restores hormone sensitivity with differential effects on estrogen
receptor signaling in cell models of human epidermal growth factor
receptor 2-negative breast cancer with acquired endocrine
resistance. Clin Cancer Res. 16:1486–1497. 2010. View Article : Google Scholar
|
|
13.
|
Shou J, Massarweh S, Osborne CK, Wakeling
AE, Ali S, Weiss H and Schiff R: Mechanisms of tamoxifen
resistance: increased estrogen receptor-HER2/neu cross-talk in
ER/HER2-positive breast cancer. J Natl Cancer Inst. 96:926–935.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Konecny GE, Pegram MD, Venkatesan N, Finn
R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith
BR, Gilmer TM, Berger M, Podratz KC and Slamon DJ: Activity of the
dual kinase inhibitor lapatinib (GW572016) against
HER-2-overexpressing and trastuzumab-treated breast cancer cells.
Cancer Res. 66:1630–1639. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Frogne T, Benjaminsen RV, Sonne-Hansen K,
Sorensen BS, Nexo E, Laenkholm AV, Rasmussen LM, Riese DJ II, de
Cremoux P, Stenvang J and Lykkesfeldt AE: Activation of ErbB3, EGFR
and Erk is essential for growth of human breast cancer cell lines
with acquired resistance to fulvestrant. Breast Cancer Res Treat.
114:263–275. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Günthert AR, Gründker C, Olota A, Läsche
J, Eicke N and Emons G: Analogs of GnRH-I and GnRH-II inhibit
epidermal growth factor-induced signal transduction and resensitize
resistant human breast cancer cells to 4OH-tamoxifen. Eur J
Endocrinol. 153:613–625. 2005.
|
|
17.
|
Emons G, Müller V, Ortmann O and Schulz
KD: Effects of LHRH-analogues on mitogenic signal transduction in
cancer cells. J Steroid Biochem Mol Biol. 65:199–206. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Gründker C, Völker P, Schulz KD and Emons
G: Luteinizing hormone-releasing hormone agonist triptorelin and
antagonist cetrorelix inhibit EGF-induced c-fos expression in human
gynecological cancers. Gynecol Oncol. 78:194–202. 2000.PubMed/NCBI
|
|
19.
|
Gründker C, Völker P and Emons G:
Antiproliferative signaling of luteinizing hormone-releasing
hormone in human endometrial and ovarian cancer cells through G
protein alpha(I)-mediated activation of phosphotyrosine
phosphatase. Endocrinology. 142:2369–2380. 2001.
|
|
20.
|
Kraus S, Levy G, Hanoch T, Naor Z and
Seger R: Gonadotropin-releasing hormone induces apoptosis of
prostate cancer cells: role of c-Jun NH2-terminal kinase, protein
kinase B, and extracellular signal-regulated kinase pathways.
Cancer Res. 64:5736–5744. 2004. View Article : Google Scholar
|
|
21.
|
Ghayad SE, Vendrell JA, Larbi SB, Dumontet
C, Bieche I and Cohen PA: Endocrine resistance associated with
activated ErbB system in breast cancer cells is reversed by
inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer.
126:545–562. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
deGraffenried LA, Friedrichs WE, Russell
DH, Donzis EJ, Middleton AK, Silva JM, Roth RA and Hidalgo M:
Inhibition of mTOR activity restores tamoxifen response in breast
cancer cells with aberrant Akt Activity. Clin Cancer Res.
10:8059–8067. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Chow LM and Baker SJ: PTEN function in
normal and neoplastic growth. Cancer Lett. 241:184–196. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Maira SM, Galetic I, Brazil DP, Kaech S,
Ingley E, Thelen M and Hemmings BA: Carboxyl-terminal modulator
protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the
plasma membrane. Science. 294:374–380. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Revankar CM, Mitchell HD, Field AS, Burai
R, Corona C, Ramesh C, Sklar LA, Arterburn JB and Prossnitz ER:
Synthetic estrogen derivatives demonstrate the functionality of
intracellular GPR30. ACS Chem Biol. 2:536–544. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Bertelsen BI, Steine SJ, Sandvei R, Molven
A and Laerum OD: Molecular analysis of the PI3K-AKT pathway in
uterine cervical neoplasia: frequent PIK3CA amplification and AKT
phosphorylation. Int J Cancer. 118:1877–1883. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Curtin JA, Stark MS, Pinkel D, Hayward NK
and Bastian BC: PI3-kinase subunits are infrequent somatic targets
in melanoma. J Invest Dermatol. 126:1660–1663. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Wilkens L, Tchinda J, Burkhardt D, Nolte
M, Werner M and Georgii A: Analysis of hematologic diseases using
conventional karyotyping, fluorescence in situ hybridization
(FISH), and comparative genomic hybridization (CGH). Hum Pathol.
29:833–839. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Eicke N, Günthert AR, Viereck V, Siebold
D, Béhé M, Becker T, Emons G and Gründker C: GnRH-II receptor-like
antigenicity in human placenta and in cancers of the human
reproductive organs. Eur J Endocrinol. 153:605–612. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Cheskis BJ, Greger J, Cooch N, McNally C,
Mclarney S, Lam HS, Rutledge S, Mekonnen B, Hauze D, Nagpal S and
Freedman LP: MNAR plays an important role in ERα activation of
Src/MAPK and PI3K/Akt signaling pathways. Steroids. 73:901–905.
2008.
|
|
31.
|
Gururaj AE, Holm C, Landberg G and Kumar
R: Breast cancer-amplified sequence 3, a target of
metastasis-associated protein 1, contributes to tamoxifen
resistance in premenopausal patients with breast cancer. Cell
Cycle. 5:1407–1410. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Kumar R, Zhang H, Holm C, Vadlamudi RK,
Landberg G and Rayala SK: Extranuclear coactivator signaling
confers insensitivity to tamoxifen. Clin Cancer Res. 15:4123–4130.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Lo TL, Yusoff P, Fong CW, Guo K, McCaw BJ,
Phillips WA, Yang H, Wong ES, Leong HF, Zeng Q, Putti TC and Guy
GR: The ras/mitogen-activated protein kinase pathway inhibitor and
likely tumor suppressor proteins, sprouty 1 and sprouty 2 are
deregulated in breast cancer. Cancer Res. 64:6127–6136. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Kurokawa H, Lenferink AE, Simpson JF,
Pisacane PI, Sliwkowski MX, Forbes JT and Arteaga CL: Inhibition of
HER2/neu (erbB-2) and mitogen-activated protein kinases enhances
tamoxifen action against HER2-overexpressing, tamoxifen-resistant
breast cancer cells. Cancer Res. 60:5887–5894. 2000.
|
|
35.
|
Massarweh S, Osborne CK, Jiang S, Wakeling
AE, Rimawi M, Mohsin SK, Hilsenbeck S and Schiff R: Mechanisms of
tumor regression and resistance to estrogen deprivation and
fulvestrant in a model of estrogen receptor-positive,
HER-2/neu-positive breast cancer. Cancer Res. 66:8266–8273. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Creighton CJ, Massarweh S, Huang S,
Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L and
Schiff R: Development of resistance to targeted therapies
transforms the clinically associated molecular profile subtype of
breast tumor xenografts. Cancer Res. 68:7493–7501. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Hutcheson IR, Knowlden JM, Madden TA,
Barrow D, Gee JM, Wakeling AE and Nicholson RI: Oestrogen
receptor-mediated modulation of the EGFR/MAPK pathway in
tamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat. 81:81–93.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Arpino G, Gutierrez C, Weiss H, Rimawi M,
Massarweh S, Bharwani L, De Placido S, Osborne CK and Schiff R:
Treatment of human epidermal growth factor receptor
2-overexpressing breast cancer xenografts with multiagent
HER-targeted therapy. J Natl Cancer Inst. 99:694–705. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Kondapaka SB, Singh SS, Dasmahapatra GP,
Sausville EA and Roy KK: Perifosine, a novel alkylphospholipid,
inhibits protein kinase B activation. Mol Cancer Ther. 2:1093–1103.
2003.PubMed/NCBI
|
|
40.
|
Knowlden JM, Jones HE, Barrow D, Gee JM,
Nicholson RI and Hutcheson IR: Insulin receptor substrate-1
involvement in epidermal growth factor receptor and insulin-like
growth factor receptor signalling: implication for Gefitinib
(‘Iressa’) response and resistance. Breast Cancer Res Treat.
111:79–91. 2008.PubMed/NCBI
|
|
41.
|
Fekete M, Wittliff JL and Schally AV:
Characteristics and distribution of receptors for
[D-TRP6]-luteinizing hormone-releasing hormone, somatostatin,
epidermal growth factor, and sex steroids in 500 biopsy samples of
human breast cancer. J Clin Lab Anal. 3:137–147. 1989.
|
|
42.
|
Baumann KH, Kiesel L, Kaufmann M, Bastert
G and Runnebaum B: Characterization of binding sites for a
GnRH-agonist (buserelin) in human breast cancer biopsies and their
distribution in relation to tumor parameters. Breast Cancer Res
Treat. 25:37–46. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Miller WR, Scott WN, Morris R, Fraser HM
and Sharpe RM: Growth of human breast cancer cells inhibited by a
luteinizing hormone-releasing hormone agonist. Nature. 313:231–233.
1985. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Foekens JA, Henkelman MS, Fukkink JF,
Blankenstein MA and Klijn JG: Combined effects of buserelin,
estradiol and tamoxifen on the growth of MCF-7 human breast cancer
cells in vitro. Biochem Biophys Res Commun. 140:550–556. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Emons G, Ortmann O, Becker M, Irmer G,
Springer B, Laun R, Hölzel F, Schulz KD and Schally AV: High
affinity binding and direct antiproliferative effects of LHRH
analogues in human ovarian cancer cell lines. Cancer Res.
53:5439–5446. 1993.PubMed/NCBI
|
|
46.
|
Gründker C, Schlotawa L, Viereck V, Eicke
N, Horst A, Kairies B and Emons G: Antiproliferative effects of the
GnRH antagonist cetrorelix and of GnRH-II on human endometrial and
ovarian cancer cells are not mediated through the GnRH type I
receptor. Eur J Endocrinol. 151:141–149. 2004.PubMed/NCBI
|
|
47.
|
Gründker C, Günthert AR, Millar RP and
Emons G: Expression of gonadotropin-releasing hormone II (GnRH-II)
receptor in human endometrial and ovarian cancer cells and effects
of GnRH-II on tumor cell proliferation. J Clin Endocrinol Metab.
87:1427–1430. 2002.PubMed/NCBI
|
|
48.
|
Buchholz S, Seitz S, Schally AV, Engel JB,
Rick FG, Szalontay L, Hohla F, Krishan A, Papadia A, Gaiser T,
Brockhoff G, Ortmann O, Diedrich K and Köster F: Triple-negative
breast cancers express receptors for luteinizing hormone-releasing
hormone (LHRH) and respond to LHRH antagonist cetrorelix with
growth inhibition. Int J Oncol. 35:789–796. 2009.
|
|
49.
|
Gründker C, Fost C, Fister S, Nolte N,
Günthert AR and Emons G: Gonadotropin-releasing hormone type II
antagonist induces apoptosis in MCF-7 and triple-negative
MDA-MB-231 human breast cancer cells in vitro and in vivo. Breast
Cancer Res. 12:R492010.PubMed/NCBI
|
|
50.
|
Fister S, Günthert AR, Aicher B, Paulini
KW, Emons G and Gründker C: GnRH-II antagonists induce apoptosis in
human endometrial, ovarian, and breast cancer cells via activation
of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax.
Cancer Res. 69:6473–6481. 2009. View Article : Google Scholar
|
